- Home
- Publications
- Publication Search
- Publication Details
Title
Bromodomains: a new target class for drug development
Authors
Keywords
-
Journal
NATURE REVIEWS DRUG DISCOVERY
Volume 18, Issue 8, Pages 609-628
Publisher
Springer Science and Business Media LLC
Online
2019-07-05
DOI
10.1038/s41573-019-0030-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- First-in-human phase I study of the bromodomain and extraterminal motif inhibitor BAY 1238097: emerging pharmacokinetic/pharmacodynamic relationship and early termination due to unexpected toxicity
- (2019) Sophie Postel-Vinay et al. EUROPEAN JOURNAL OF CANCER
- Bromodomain inhibition of the coactivators CBP/EP300 facilitate cellular reprogramming
- (2019) Ayyub Ebrahimi et al. Nature Chemical Biology
- BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design
- (2019) William Farnaby et al. Nature Chemical Biology
- Quantitative Characterization of Bivalent Probes for a Dual Bromodomain Protein, Transcription Initiation Factor TFIID Subunit 1
- (2018) Junghyun L. Suh et al. BIOCHEMISTRY
- Exploiting a water network to achieve enthalpy-driven, bromodomain-selective BET inhibitors
- (2018) William R. Shadrick et al. BIOORGANIC & MEDICINAL CHEMISTRY
- BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency
- (2018) Chaoyang Sun et al. CANCER CELL
- Discovery and optimization of 1-(1 H -indol-1-yl)ethanone derivatives as CBP/EP300 bromodomain inhibitors for the treatment of castration-resistant prostate cancer
- (2018) Qiuping Xiang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer
- (2018) Andrew J. Wilson et al. GYNECOLOGIC ONCOLOGY
- The BRD3 ET domain recognizes a short peptide motif through a mechanism that is conserved across chromatin remodelers and transcriptional regulators
- (2018) Dorothy C. C. Wai et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression
- (2018) Chong Qin et al. JOURNAL OF MEDICINAL CHEMISTRY
- Functional TRIM24 degrader via conjugation of ineffectual bromodomain and VHL ligands
- (2018) Lara N. Gechijian et al. Nature Chemical Biology
- An inhibitor of oxidative phosphorylation exploits cancer vulnerability
- (2018) Jennifer R. Molina et al. NATURE MEDICINE
- Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer
- (2018) Yonathan Lissanu Deribe et al. NATURE MEDICINE
- The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma
- (2018) A. Esteve-Arenys et al. ONCOGENE
- Spatially constrained tandem bromodomain inhibition bolsters sustained repression of BRD4 transcriptional activity for TNBC cell growth
- (2018) Chunyan Ren et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Modulating PCAF/GCN5 Immune Cell Function through a PROTAC Approach
- (2018) Zuni I. Bassi et al. ACS Chemical Biology
- Quantitative Live-Cell Kinetic Degradation and Mechanistic Profiling of PROTAC Mode of Action
- (2018) Kristin M. Riching et al. ACS Chemical Biology
- Structure-Guided Design and Development of Potent and Selective Dual Bromodomain 4 (BRD4)/Polo-like Kinase 1 (PLK1) Inhibitors
- (2018) Shuai Liu et al. JOURNAL OF MEDICINAL CHEMISTRY
- DUB3 Promotes BET Inhibitor Resistance and Cancer Progression by Deubiquitinating BRD4
- (2018) Xin Jin et al. MOLECULAR CELL
- The ZZ domain of p300 mediates specificity of the adjacent HAT domain for histone H3
- (2018) Yi Zhang et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Enhancer Activity Requires CBP/P300 Bromodomain-Dependent Histone H3K27 Acetylation
- (2018) Ryan Raisner et al. Cell Reports
- Modular Organization and Assembly of SWI/SNF Family Chromatin Remodeling Complexes
- (2018) Nazar Mashtalir et al. CELL
- Discovery of Orally Active Inhibitors of Brahma Homolog (BRM)/SMARCA2 ATPase Activity for the Treatment of Brahma Related Gene 1 (BRG1)/SMARCA4-Mutant Cancers
- (2018) Julien P. N. Papillon et al. JOURNAL OF MEDICINAL CHEMISTRY
- GNE-371, a Potent and Selective Chemical Probe for the Second Bromodomains of Human Transcription-Initiation-Factor TFIID Subunit 1 and Transcription-Initiation-Factor TFIID Subunit 1-like
- (2018) Shumei Wang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Iterative Design and Optimization of Initially Inactive Proteolysis Targeting Chimeras (PROTACs) Identify VZ185 as a Potent, Fast, and Selective von Hippel–Lindau (VHL) Based Dual Degrader Probe of BRD9 and BRD7
- (2018) Vittoria Zoppi et al. JOURNAL OF MEDICINAL CHEMISTRY
- A non-canonical SWI/SNF complex is a synthetic lethal target in cancers driven by BAF complex perturbation
- (2018) Brittany C. Michel et al. NATURE CELL BIOLOGY
- The polar warhead of a TRIM24 bromodomain inhibitor rearranges a water-mediated interaction network
- (2017) Jiuyang Liu et al. FEBS Journal
- Bromodomain and extraterminal inhibitors block the Epstein-Barr virus lytic cycle at two distinct steps
- (2017) Kristin M. Keck et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Individual Bromodomains of Polybromo-1 Contribute to Chromatin Association and Tumor Suppression in Clear Cell Renal Carcinoma
- (2017) Elizabeth G. Porter et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Biological function and histone recognition of family IV bromodomain-containing proteins
- (2017) Jonathan T. Lloyd et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Design of a Biased Potent Small Molecule Inhibitor of the Bromodomain and PHD Finger-Containing (BRPF) Proteins Suitable for Cellular and in Vivo Studies
- (2017) Niall Igoe et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of a Potent, Cell Penetrant, and Selective p300/CBP-Associated Factor (PCAF)/General Control Nonderepressible 5 (GCN5) Bromodomain Chemical Probe
- (2017) Philip G. Humphreys et al. JOURNAL OF MEDICINAL CHEMISTRY
- A “Click Chemistry Platform” for the Rapid Synthesis of Bispecific Molecules for Inducing Protein Degradation
- (2017) Ryan P. Wurz et al. JOURNAL OF MEDICINAL CHEMISTRY
- Impact of Target Warhead and Linkage Vector on Inducing Protein Degradation: Comparison of Bromodomain and Extra-Terminal (BET) Degraders Derived from Triazolodiazepine (JQ1) and Tetrahydroquinoline (I-BET726) BET Inhibitor Scaffolds
- (2017) Kwok-Ho Chan et al. JOURNAL OF MEDICINAL CHEMISTRY
- Drug Discovery Targeting Bromodomain-Containing Protein 4
- (2017) Zhiqing Liu et al. JOURNAL OF MEDICINAL CHEMISTRY
- GNE-781, A Highly Advanced Potent and Selective Bromodomain Inhibitor of Cyclic Adenosine Monophosphate Response Element Binding Protein, Binding Protein (CBP)
- (2017) F. Anthony Romero et al. JOURNAL OF MEDICINAL CHEMISTRY
- Benzoisoquinolinediones as Potent and Selective Inhibitors of BRPF2 and TAF1/TAF1L Bromodomains
- (2017) Léa Bouché et al. JOURNAL OF MEDICINAL CHEMISTRY
- Design of a Chemical Probe for the Bromodomain and Plant Homeodomain Finger-Containing (BRPF) Family of Proteins
- (2017) Niall Igoe et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression
- (2017) Bing Zhou et al. JOURNAL OF MEDICINAL CHEMISTRY
- Bromodomain Histone Readers and Cancer
- (2017) Abhinav K Jain et al. JOURNAL OF MOLECULAR BIOLOGY
- Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells
- (2017) D T Saenz et al. LEUKEMIA
- BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells
- (2017) B Sun et al. LEUKEMIA
- Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia
- (2017) S Peirs et al. LEUKEMIA
- Identification of potential ibrutinib combinations in hematological malignancies using a combination high-throughput screen
- (2017) Michael Schaffer et al. LEUKEMIA & LYMPHOMA
- Potent Dual BET Bromodomain-Kinase Inhibitors as Value-Added Multitargeted Chemical Probes and Cancer Therapeutics
- (2017) Stuart W. Ember et al. MOLECULAR CANCER THERAPEUTICS
- Vulnerability of Small-Cell Lung Cancer to Apoptosis Induced by the Combination of BET Bromodomain Proteins and BCL2 Inhibitors
- (2017) Lloyd T. Lam et al. MOLECULAR CANCER THERAPEUTICS
- RVX-297, a BET Bromodomain Inhibitor, Has Therapeutic Effects in Preclinical Models of Acute Inflammation and Autoimmune Disease
- (2017) Ravi Jahagirdar et al. MOLECULAR PHARMACOLOGY
- Structural basis of PROTAC cooperative recognition for selective protein degradation
- (2017) Morgan S Gadd et al. Nature Chemical Biology
- Prostate cancer–associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4
- (2017) Xiangpeng Dai et al. NATURE MEDICINE
- Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT–mTORC1 activation
- (2017) Pingzhao Zhang et al. NATURE MEDICINE
- Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors
- (2017) Hana Janouskova et al. NATURE MEDICINE
- Marked for death: targeting epigenetic changes in cancer
- (2017) Sophia Xiao Pfister et al. NATURE REVIEWS DRUG DISCOVERY
- Functions of bromodomain-containing proteins and their roles in homeostasis and cancer
- (2017) Takao Fujisawa et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Targeted protein degradation by PROTACs
- (2017) Taavi K. Neklesa et al. PHARMACOLOGY & THERAPEUTICS
- BET N-terminal bromodomain inhibition selectively blocks Th17 cell differentiation and ameliorates colitis in mice
- (2017) Kalung Cheung et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Role of the CBP catalytic core in intramolecular SUMOylation and control of histone H3 acetylation
- (2017) Sangho Park et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies
- (2017) Stephen E. Kurtz et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- BET bromodomain inhibition suppresses innate inflammatory and profibrotic transcriptional networks in heart failure
- (2017) Qiming Duan et al. Science Translational Medicine
- Downregulation of the Complement Cascade In Vitro, in Mice and in Patients with Cardiovascular Disease by the BET Protein Inhibitor Apabetalone (RVX-208)
- (2017) Sylwia Wasiak et al. Journal of Cardiovascular Translational Research
- GNE-886: A Potent and Selective Inhibitor of the Cat Eye Syndrome Chromosome Region Candidate 2 Bromodomain (CECR2)
- (2017) Terry D. Crawford et al. ACS Medicinal Chemistry Letters
- DNA binding drives the association of BRG1/hBRM bromodomains with nucleosomes
- (2017) Emma A. Morrison et al. Nature Communications
- Non-canonical reader modules of BAZ1A promote recovery from DNA damage
- (2017) Mariano Oppikofer et al. Nature Communications
- Selective BET bromodomain inhibition as an antifungal therapeutic strategy
- (2017) Flore Mietton et al. Nature Communications
- BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1
- (2017) Simon J. Hogg et al. Cell Reports
- BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer
- (2017) Sergey Karakashev et al. Cell Reports
- Targeting Cancer Cells with BET Bromodomain Inhibitors
- (2017) Yali Xu et al. Cold Spring Harbor Perspectives in Medicine
- Discovery of a PCAF Bromodomain Chemical Probe
- (2016) Moses Moustakim et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- A Chemical Probe for the ATAD2 Bromodomain
- (2016) Paul Bamborough et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease
- (2016) Dean Gilham et al. ATHEROSCLEROSIS
- Bromodomains: Structure, function and pharmacology of inhibition
- (2016) Elena Ferri et al. BIOCHEMICAL PHARMACOLOGY
- Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response
- (2016) Andrew R. Conery et al. CANCER RESEARCH
- Serelaxin in acute heart failure: Most recent update on clinical and preclinical evidence
- (2016) Raktim Kumar Ghosh et al. Cardiovascular Therapeutics
- Functional Genomic Landscape of Human Breast Cancer Drivers, Vulnerabilities, and Resistance
- (2016) Richard Marcotte et al. CELL
- Progress in the Development of non-BET Bromodomain Chemical Probes
- (2016) Natalie H. Theodoulou et al. ChemMedChem
- AMPK–ULK1-Mediated Autophagy Confers Resistance to BET Inhibitor JQ1 in Acute Myeloid Leukemia Stem Cells
- (2016) Ji Eun Jang et al. CLINICAL CANCER RESEARCH
- The MAPK Pathway Regulates Intrinsic Resistance to BET Inhibitors in Colorectal Cancer
- (2016) Yufang Ma et al. CLINICAL CANCER RESEARCH
- Clinical progress and pharmacology of small molecule bromodomain inhibitors
- (2016) Natalie H Theodoulou et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Bromodomain inhibitors and cancer therapy: From structures to applications
- (2016) Montserrat Pérez-Salvia et al. Epigenetics
- Regulatory T Cell Modulation by CBP/EP300 Bromodomain Inhibition
- (2016) Srimoyee Ghosh et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models
- (2016) Yuki Kagoya et al. JOURNAL OF CLINICAL INVESTIGATION
- Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay
- (2016) Maria Pia Abruzzese et al. Journal of Hematology & Oncology
- Exploring Selective Inhibition of the First Bromodomain of the Human Bromodomain and Extra-terminal Domain (BET) Proteins
- (2016) Brigitt Raux et al. JOURNAL OF MEDICINAL CHEMISTRY
- Identification and Development of 2,3-Dihydropyrrolo[1,2-a]quinazolin-5(1H)-one Inhibitors Targeting Bromodomains within the Switch/Sucrose Nonfermenting Complex
- (2016) Charlotte L. Sutherell et al. JOURNAL OF MEDICINAL CHEMISTRY
- An Advanced Tool To Interrogate BRD9
- (2016) Rezaul M. Karim et al. JOURNAL OF MEDICINAL CHEMISTRY
- Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor
- (2016) Laetitia J. Martin et al. JOURNAL OF MEDICINAL CHEMISTRY
- Identification of a Chemical Probe for Family VIII Bromodomains through Optimization of a Fragment Hit
- (2016) Brian S. Gerstenberger et al. JOURNAL OF MEDICINAL CHEMISTRY
- Dual Kinase-Bromodomain Inhibitors in Anticancer Drug Discovery: A Structural and Pharmacological Perspective
- (2016) Luca Carlino et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of a Potent and Selective in Vivo Probe (GNE-272) for the Bromodomains of CBP/EP300
- (2016) Terry D. Crawford et al. JOURNAL OF MEDICINAL CHEMISTRY
- Diving into the Water: Inducible Binding Conformations for BRD4, TAF1(2), BRD9, and CECR2 Bromodomains
- (2016) Terry D. Crawford et al. JOURNAL OF MEDICINAL CHEMISTRY
- Effects of the BET-inhibitor, RVX-208 on the HDL lipidome and glucose metabolism in individuals with prediabetes: A randomized controlled trial
- (2016) Andrew L. Siebel et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer
- (2016) I. A. Asangani et al. MOLECULAR CANCER RESEARCH
- Exploitation of Castration-Resistant Prostate Cancer Transcription Factor Dependencies by the Novel BET Inhibitor ABBV-075
- (2016) Emily J. Faivre et al. MOLECULAR CANCER RESEARCH
- HEXIM1 as a Robust Pharmacodynamic Marker for Monitoring Target Engagement of BET Family Bromodomain Inhibitors in Tumors and Surrogate Tissues
- (2016) Xiaoyu Lin et al. MOLECULAR CANCER THERAPEUTICS
- Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma
- (2016) A. R. Singh et al. MOLECULAR CANCER THERAPEUTICS
- AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies
- (2016) G. W. Rhyasen et al. MOLECULAR CANCER THERAPEUTICS
- Bet on drug resistance
- (2016) Jeff Settleman NATURE
- Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer
- (2016) Shaokun Shu et al. NATURE
- Mapping the chemical chromatin reactivation landscape identifies BRD4-TAF1 cross-talk
- (2016) Sara Sdelci et al. Nature Chemical Biology
- Sensitivity and engineered resistance of myeloid leukemia cells to BRD9 inhibition
- (2016) Anja F Hohmann et al. Nature Chemical Biology
- Potent and selective bivalent inhibitors of BET bromodomains
- (2016) Michael J Waring et al. Nature Chemical Biology
- Design and characterization of bivalent BET inhibitors
- (2016) Minoru Tanaka et al. Nature Chemical Biology
- Induced protein degradation: an emerging drug discovery paradigm
- (2016) Ashton C. Lai et al. NATURE REVIEWS DRUG DISCOVERY
- Epigenetic drug discovery: breaking through the immune barrier
- (2016) David F. Tough et al. NATURE REVIEWS DRUG DISCOVERY
- Loss of TRIM33 causes resistance to BET bromodomain inhibitors through MYC- and TGF-β–dependent mechanisms
- (2016) Xiarong Shi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer
- (2016) Kanak Raina et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- GSK6853, a Chemical Probe for Inhibition of the BRPF1 Bromodomain
- (2016) Paul Bamborough et al. ACS Medicinal Chemistry Letters
- Fragment-Based Discovery of a Selective and Cell-Active Benzodiazepinone CBP/EP300 Bromodomain Inhibitor (CPI-637)
- (2016) Alexander M. Taylor et al. ACS Medicinal Chemistry Letters
- Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628
- (2016) A. Stathis et al. Cancer Discovery
- BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression
- (2016) Hengrui Zhu et al. Cell Reports
- Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer
- (2016) Alison M. Kurimchak et al. Cell Reports
- High-Resolution Mapping of RNA Polymerases Identifies Mechanisms of Sensitivity and Resistance to BET Inhibitors in t(8;21) AML
- (2016) Yue Zhao et al. Cell Reports
- Exploitation of EP300 and CREBBP Lysine Acetyltransferases by Cancer
- (2016) Narsis Attar et al. Cold Spring Harbor Perspectives in Medicine
- Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma
- (2016) Andrew R Conery et al. eLife
- Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study
- (2016) Céline Berthon et al. Lancet Haematology
- Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study
- (2016) Sandy Amorim et al. Lancet Haematology
- Protein Degradation by In-Cell Self-Assembly of Proteolysis Targeting Chimeras
- (2016) Honorine Lebraud et al. ACS Central Science
- Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4
- (2015) Michael Zengerle et al. ACS Chemical Biology
- LP99: Discovery and Synthesis of the First Selective BRD7/9 Bromodomain Inhibitor
- (2015) Peter G. K. Clark et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- MOZ and MORF acetyltransferases: Molecular interaction, animal development and human disease
- (2015) Xiang-Jiao Yang BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy
- (2015) Elias E. Stratikopoulos et al. CANCER CELL
- Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy
- (2015) S. Picaud et al. CANCER RESEARCH
- The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies
- (2015) Bhavatarini Vangamudi et al. CANCER RESEARCH
- Transcriptional Profiling of a Selective CREB Binding Protein Bromodomain Inhibitor Highlights Therapeutic Opportunities
- (2015) Eugene L. Piatnitski Chekler et al. CHEMISTRY & BIOLOGY
- Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
- (2015) Jing Lu et al. CHEMISTRY & BIOLOGY
- Binding Mode of Acetylated Histones to Bromodomains: Variations on a Common Motif
- (2015) Jean-Rémy Marchand et al. ChemMedChem
- Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic Malignancies
- (2015) Elodie Odore et al. CLINICAL PHARMACOKINETICS
- Structure-Based Optimization of Naphthyridones into Potent ATAD2 Bromodomain Inhibitors
- (2015) Paul Bamborough et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery and Characterization of GSK2801, a Selective Chemical Probe for the Bromodomains BAZ2A and BAZ2B
- (2015) Peiling Chen et al. JOURNAL OF MEDICINAL CHEMISTRY
- 9H-Purine Scaffold Reveals Induced-Fit Pocket Plasticity of the BRD9 Bromodomain
- (2015) Sarah Picaud et al. JOURNAL OF MEDICINAL CHEMISTRY
- Structure Enabled Design of BAZ2-ICR, A Chemical Probe Targeting the Bromodomains of BAZ2A and BAZ2B
- (2015) Ludovic Drouin et al. JOURNAL OF MEDICINAL CHEMISTRY
- Fragment-Based Discovery of Low-Micromolar ATAD2 Bromodomain Inhibitors
- (2015) Emmanuel H. Demont et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of a Chemical Tool Inhibitor Targeting the Bromodomains of TRIM24 and BRPF
- (2015) James Bennett et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of I-BRD9, a Selective Cell Active Chemical Probe for Bromodomain Containing Protein 9 Inhibition
- (2015) Natalie H. Theodoulou et al. JOURNAL OF MEDICINAL CHEMISTRY
- Structure-Guided Design of IACS-9571, a Selective High-Affinity Dual TRIM24-BRPF1 Bromodomain Inhibitor
- (2015) Wylie S. Palmer et al. JOURNAL OF MEDICINAL CHEMISTRY
- Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors
- (2015) Xu Ran et al. JOURNAL OF MEDICINAL CHEMISTRY
- Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain Inhibitors
- (2015) F. Anthony Romero et al. JOURNAL OF MEDICINAL CHEMISTRY
- ABT-199, a BH3 mimetic that specifically targets Bcl-2, enhances the antitumor activity of chemotherapy, bortezomib and JQ1 in “double hit” lymphoma cells
- (2015) Nadine Johnson-Farley et al. LEUKEMIA & LYMPHOMA
- Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents
- (2015) Madhusoodanan Mottamal et al. MOLECULES
- Transcriptional plasticity promotes primary and acquired resistance to BET inhibition
- (2015) Philipp Rathert et al. NATURE
- BET inhibitor resistance emerges from leukaemia stem cells
- (2015) Chun Yew Fong et al. NATURE
- The promise and peril of chemical probes
- (2015) Cheryl H Arrowsmith et al. Nature Chemical Biology
- The influence of subclonal resistance mutations on targeted cancer therapy
- (2015) Michael W. Schmitt et al. Nature Reviews Clinical Oncology
- CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses
- (2015) Ariane Hammitzsch et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Phthalimide conjugation as a strategy for in vivo target protein degradation
- (2015) G. E. Winter et al. SCIENCE
- A Subset of Human Bromodomains Recognizes Butyryllysine and Crotonyllysine Histone Peptide Modifications
- (2015) E. Megan Flynn et al. STRUCTURE
- Design and synthesis of potent and selective inhibitors of BRD7 and BRD9 bromodomains
- (2015) Duncan A. Hay et al. MedChemComm
- Mitochondrial protection impairs BET bromodomain inhibitor-mediated cell death and provides rationale for combination therapeutic strategies
- (2015) E Lasorsa et al. Cell Death & Disease
- BRD4 Structure–Activity Relationships of Dual PLK1 Kinase/BRD4 Bromodomain Inhibitor BI-2536
- (2015) Lijia Chen et al. ACS Medicinal Chemistry Letters
- Targeting p300 Addiction in CBP-Deficient Cancers Causes Synthetic Lethality by Apoptotic Cell Death due to Abrogation of MYC Expression
- (2015) H. Ogiwara et al. Cancer Discovery
- Large-Scale Computational Screening Identifies First in Class Multitarget Inhibitor of EGFR Kinase and BRD4
- (2015) Bryce K. Allen et al. Scientific Reports
- Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains
- (2015) Timothy J. Stuhlmiller et al. Cell Reports
- Bromodomain Proteins Contribute to Maintenance of Bloodstream Form Stage Identity in the African Trypanosome
- (2015) Danae Schulz et al. PLOS BIOLOGY
- Selective targeting of the BRG/PB1 bromodomains impairs embryonic and trophoblast stem cell maintenance
- (2015) O. Fedorov et al. Science Advances
- Mammalian SWI/SNF chromatin remodeling complexes and cancer: Mechanistic insights gained from human genomics
- (2015) C. Kadoch et al. Science Advances
- Acetyl-lysine Binding Site of Bromodomain-Containing Protein 4 (BRD4) Interacts with Diverse Kinase Inhibitors
- (2014) Stuart W. J. Ember et al. ACS Chemical Biology
- Small Molecule Inhibitors of Bromodomain–Acetyl-lysine Interactions
- (2014) Michael Brand et al. ACS Chemical Biology
- The bromodomain: From epigenome reader to druggable target
- (2014) Roberto Sanchez et al. Biochimica et Biophysica Acta-Gene Regulatory Mechanisms
- Disrupting the Interaction of BRD4 with Diacetylated Twist Suppresses Tumorigenesis in Basal-like Breast Cancer
- (2014) Jian Shi et al. CANCER CELL
- Selective Chemical Modulation of Gene Transcription Favors Oligodendrocyte Lineage Progression
- (2014) Mar Gacias et al. CHEMISTRY & BIOLOGY
- Phenotypic screening and fragment-based approaches to the discovery of small-molecule bromodomain ligands
- (2014) Laura E Jennings et al. Future Medicinal Chemistry
- Structure-Guided Design and Optimization of Small Molecules Targeting the Protein–Protein Interaction between the von Hippel–Lindau (VHL) E3 Ubiquitin Ligase and the Hypoxia Inducible Factor (HIF) Alpha Subunit with in Vitro Nanomolar Affinities
- (2014) Carles Galdeano et al. JOURNAL OF MEDICINAL CHEMISTRY
- Fragment-Based Screening of the Bromodomain of ATAD2
- (2014) Mary J. Harner et al. JOURNAL OF MEDICINAL CHEMISTRY
- The Discovery of I-BET726 (GSK1324726A), a Potent Tetrahydroquinoline ApoA1 Up-Regulator and Selective BET Bromodomain Inhibitor
- (2014) Romain Gosmini et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery and Optimization of Small-Molecule Ligands for the CBP/p300 Bromodomains
- (2014) Duncan A. Hay et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma
- (2014) A Moros et al. LEUKEMIA
- BET Protein Antagonist JQ1 Is Synergistically Lethal with FLT3 Tyrosine Kinase Inhibitor (TKI) and Overcomes Resistance to FLT3-TKI in AML Cells Expressing FLT-ITD
- (2014) W. Fiskus et al. MOLECULAR CANCER THERAPEUTICS
- The Mechanisms behind the Therapeutic Activity of BET Bromodomain Inhibition
- (2014) Junwei Shi et al. MOLECULAR CELL
- Lessons from Yeast on Emerging Roles of the ATAD2 Protein Family in Gene Regulation and Genome Organization
- (2014) Matteo Cattaneo et al. MOLECULES AND CELLS
- Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer
- (2014) Irfan A. Asangani et al. NATURE
- Dual kinase-bromodomain inhibitors for rationally designed polypharmacology
- (2014) Pietro Ciceri et al. Nature Chemical Biology
- ARID1B is a specific vulnerability in ARID1A-mutant cancers
- (2014) Katherine C Helming et al. NATURE MEDICINE
- Targeting bromodomains: epigenetic readers of lysine acetylation
- (2014) Panagis Filippakopoulos et al. NATURE REVIEWS DRUG DISCOVERY
- Blockade of oncogenic I B kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors
- (2014) M. Ceribelli et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers
- (2014) G. R. Hoffman et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- 1,3-Dimethyl Benzimidazolones Are Potent, Selective Inhibitors of the BRPF1 Bromodomain
- (2014) Emmanuel H. Demont et al. ACS Medicinal Chemistry Letters
- Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients
- (2014) B A Walker et al. Blood Cancer Journal
- The Commonly Used PI3-Kinase Probe LY294002 Is an Inhibitor of BET Bromodomains
- (2013) Antje Dittmann et al. ACS Chemical Biology
- Cyclin-Dependent Kinase Inhibitor Dinaciclib Interacts with the Acetyl-Lysine Recognition Site of Bromodomains
- (2013) Mathew P. Martin et al. ACS Chemical Biology
- Malignant genome reprogramming by ATAD2
- (2013) Fayçal Boussouar et al. Biochimica et Biophysica Acta-Gene Regulatory Mechanisms
- A Synthetic Lethality-Based Strategy to Treat Cancers Harboring a Genetic Deficiency in the Chromatin Remodeling Factor BRG1
- (2013) T. Oike et al. CANCER RESEARCH
- BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism
- (2013) Daniela Boehm et al. CELL CYCLE
- Structured Water Molecules in the Binding Site of Bromodomains Can Be Displaced by Cosolvent
- (2013) Danzhi Huang et al. ChemMedChem
- Molecular Pathways: SWI/SNF (BAF) Complexes Are Frequently Mutated in Cancer--Mechanisms and Potential Therapeutic Insights
- (2013) X. Wang et al. CLINICAL CANCER RESEARCH
- Crosstalk between epigenetic readers regulates the MOZ/MORF HAT complexes
- (2013) Brianna J Klein et al. Epigenetics
- BET bromodomain inhibition suppresses TH17-mediated pathology
- (2013) Deanna A. Mele et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Polypharmacology – Foe or Friend?
- (2013) Jens-Uwe Peters JOURNAL OF MEDICINAL CHEMISTRY
- Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia
- (2013) M A Dawson et al. LEUKEMIA
- Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy
- (2013) Cigall Kadoch et al. NATURE GENETICS
- Structure of the p300 catalytic core and implications for chromatin targeting and HAT regulation
- (2013) Manuela Delvecchio et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Molecular recognition by the KIX domain and its role in gene regulation
- (2013) J. K. Thakur et al. NUCLEIC ACIDS RESEARCH
- RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain
- (2013) S. Picaud et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- From ApoA1 upregulation to BET family bromodomain inhibition: Discovery of I-BET151
- (2012) Olivier Mirguet et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family
- (2012) Panagis Filippakopoulos et al. CELL
- Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies
- (2012) D. Mahadevan et al. EUROPEAN JOURNAL OF CANCER
- Druggability Analysis and Structural Classification of Bromodomain Acetyl-lysine Binding Sites
- (2012) Lewis R. Vidler et al. JOURNAL OF MEDICINAL CHEMISTRY
- Progress in the Development and Application of Small Molecule Inhibitors of Bromodomain–Acetyl-lysine Interactions
- (2012) David S. Hewings et al. JOURNAL OF MEDICINAL CHEMISTRY
- Epigenetic protein families: a new frontier for drug discovery
- (2012) Cheryl H. Arrowsmith et al. NATURE REVIEWS DRUG DISCOVERY
- The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation
- (2012) Zichong Li et al. NUCLEIC ACIDS RESEARCH
- A Poised Chromatin Platform for TGF-β Access to Master Regulators
- (2011) Qiaoran Xi et al. CELL
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- A Small Molecule Binding to the Coactivator CREB-Binding Protein Blocks Apoptosis in Cardiomyocytes
- (2011) Jagat C. Borah et al. CHEMISTRY & BIOLOGY
- Structural Basis and Specificity of Acetylated Transcription Factor GATA1 Recognition by BET Family Bromodomain Protein Brd3
- (2011) R. Gamsjaeger et al. MOLECULAR AND CELLULAR BIOLOGY
- Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
- (2011) Mark A. Dawson et al. NATURE
- Targeting MYC dependence in cancer by inhibiting BET bromodomains
- (2011) J. A. Mertz et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Bromodomain protein Brd3 associates with acetylated GATA1 to promote its chromatin occupancy at erythroid target genes
- (2011) J. M. Lamonica et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Transcription cofactors TRIM24, TRIM28, and TRIM33 associate to form regulatory complexes that suppress murine hepatocellular carcinoma
- (2011) B. Herquel et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Interaction of Propionylated and Butyrylated Histone H3 Lysine Marks with Brd4 Bromodomains
- (2010) Friederike Vollmuth et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
- (2010) Sreenath V. Sharma et al. CELL
- TRIM24 links a non-canonical histone signature to breast cancer
- (2010) Wen-Wei Tsai et al. NATURE
- Selective inhibition of BET bromodomains
- (2010) Panagis Filippakopoulos et al. NATURE
- Oncogenesis Caused by Loss of the SNF5 Tumor Suppressor Is Dependent on Activity of BRG1, the ATPase of the SWI/SNF Chromatin Remodeling Complex
- (2009) X. Wang et al. CANCER RESEARCH
- Brd4 Coactivates Transcriptional Activation of NF- B via Specific Binding to Acetylated RelA
- (2008) B. Huang et al. MOLECULAR AND CELLULAR BIOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now